Neuromedica, Inc.

USA As Represented by Secretary of the Navy

Luitpold Pharmaceuticals, Inc.

Protarga, Inc.

Matthews O Bradley

Nigel L Webb

Victor E Shashoua

Charles S Swindell

Taffy J Williams

Che-Hung Lee

Glenn D Hoke

Forrest H Anthony

Mark Fisher

The invention provides conjugates of fatty acids and pharmaceutical agents useful in treating noncentral nervous system conditions. Methods for selectively targeting pharmaceutical agents to desired tissues are provided.

Fatty acid-pharmaceutical agent conjugates

The invention provides conjugates of fatty acids and anticancer agents useful in treating cancer, and compositions and formulations thereof. Methods for using the conjugates also are provided.

Fatty acid-anticancer conjugates and uses thereof

The invention provides conjugates of cis-docosahexaenoic acid and pharmaceutical agents useful in treating noncentral nervous system conditions. Methods for selectively targeting pharmaceutical agents to desired tissues are provided.

DHA-pharmaceutical agent conjugates of taxanes

Dha-pharmaceutical agent conjugates to improve tissue selectivity

The invention provides conjugates of fatty acids and antiviral agents useful in treating liver disorders.

Method of treating a liver disorder with fatty acid-antiviral agent conjugates

The invention provides compositions that include conjugates of a fatty acid molecule, preferably cis-docosahexaenoic acid, and clozapine. The conjugates are useful in treating psychological disorders such as schizophrenia.

Clozapine compositions and uses thereof

The invention provides taxanes that are conjugates of cis-docosahexaenoic acid and taxotere. The conjugates are useful in treating cancer.

Taxanes

The invention provides compositions that include conjugates of a cholinergic agent and a fatty acid, preferably cis-docosahexaenoic acid. The conjugates are useful in treating disorders resulting from cerebral ischemia including stroke.

Cholinergic compositions and uses thereof

The invention provides compositions that include conjugates of a fatty acid molecule, preferably cis-docosahexaenoic acid, and antipsychotic agents. The conjugates are usefull in treating psychotic conditions such as schizophrenia.

Fatty acid-antipsychotic compositions and uses thereof

The invention provides taxanes that are conjugates of cis-docosahexaenoic acid and paclitaxel. The conjugates are useful in treating cancer.

Taxane compounds and compositions

The invention provides conjugates of cis-docosahexaenoic acid and taxanes useful in treating cell proliferative disorders. Conjugates of paclitaxel and docetaxel are preferred.

Antisense oligonucleotides complementary to human mRNAs or pre-mRNAs coding or VCAM-I are used in a therapeutic treatment of sepsis (sepsis, the sepsis syndrome, septic shock and all other manifestations of the sepsis disease, including but not inclusive of, adult respiratory distress syndrome, multi-organ failure, or cardiovascular dysfunction).

Antisense oligonucleotides directed against human VCAM-1 RNA

The present invention provides a method for the treatment of septic shock d inflammatory complications of shock. A process for selectively inhibiting the expression of the human ELAM-I mRNA transcript using at least one oligonucleotide which is substantially complementary to at least a portion of the ELAM-I gene is disclosed, as are composition comprising the oligonucleotide.

Antisense oligonucleotides directed against human ELAM-I RNA

The present invention provides a method for the treatment of septic shock and inflammatory complications of shock. A process for selectively inhibiting the expression of the human ICAM-I mRNA transcript using at least one oligonucleotide which is complementary to at least a portion of the human ICAM-I mRNA is disclosed, as are oligonucleotides which are complementary to portions of the ICAM-I mRNA and compositions comprising the oligonucleotides.

Growing community of inventors

Laytonsville, MD, United States of America

Matthews O Bradley